Zentalis Q4 2022 Earnings Report
Key Takeaways
Zentalis Pharmaceuticals reported a cash balance of $437.4 million as of December 31, 2022, projecting a cash runway into Q2 2025. The company is focused on advancing its clinical development strategy for azenosertib and ZN-d5.
On track to declare monotherapy RP2D for azenosertib in 1H 2023.
Pursuing Cyclin E1 as a patient enrichment strategy for azenosertib monotherapy in ovarian cancer.
Initiated enrollment in Phase 1/2 azenosertib + BEACON regimen combination study in BRAF V600E mutated mCRC.
Enrollment ongoing in clinical trials investigating ZN-d5 in (AL) amyloidosis.
Zentalis
Zentalis
Forward Guidance
Zentalis is focused on several key milestones in 2023, including declaring the RP2D for azenosertib, advancing the Cyclin E1 enrichment strategy, presenting clinical data for ZN-d5, and continuing enrollment in ongoing clinical trials.
Positive Outlook
- Declaring a monotherapy RP2D for azenosertib in the first half of 2023.
- Presenting Cyclin E1 preclinical data in the first half of 2023.
- Reporting results from the Phase 1b chemotherapy combination clinical trial in ovarian cancer in the second half of 2023.
- Announcing interim clinical data and declare the RP2D for the Phase 1/2 monotherapy clinical trial of ZN-d5 in relapsed or refractory light chain (AL) amyloidosis in the second half of 2023.
- Providing preliminary data from the Phase 1/2 combination study of ZN-d5 and azenosertib in AML in the second half of 2023.
Challenges Ahead
- Limited operating history may make it difficult to evaluate the business and predict future success.
- The company has and expects to continue to incur significant losses.
- The company needs additional funding, which may not be available.
- Substantial dependence on the success of lead product candidates.
- Potential unforeseen events during clinical trials could cause delays or other adverse consequences.